Spero Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
675 Massachusetts Ave Ste 14, Cambridge,...Phone Number
(857) 242-1600Website
www.sperotherapeutics.comRevenue
$43 MillionStock Symbol
SPROIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Spero Therapeutics
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.Explore more
Spero Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spero Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Spero Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Spero Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Spero Therapeutics had a recent Job posting/layoffs
Check out if Spero Therapeutics is spiking on competitors!
Earning: See what the market has to say on Spero Therapeutics recently announced quarterly report
Product Launch: Get notified when Spero Therapeutics launches new products
Spero Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Spero Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Spero Therapeutics
Compare insights from companies similar to Spero Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Spero Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spero Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spero Therapeutics.
Spero Therapeutics financials insights
Gather financial insights about Spero Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$33M
2016
Series B
$30M
2017
Series C
$51.7M
Grant
$6.8M
2018
Grant
$54.2M
2019
Grant
$5.9M
2021
Debt
$125M
Spero Therapeutics Tech Stack
Most Recent Scoops
Partnership
Project
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Person-Based
Partnership
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Product Launch, Pharmaceuticals
Spero Therapeutics News & Media
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease. PresiSpero Therapeutics (SPRO) widens Q2 loss but lands $105M non-dilutive financing
Spero reported Q2 2026 net loss of $9.6M with no revenue, gained FDA approval for Utebzi, advanced SP001 in immunology, and closed a $105M non-recourse, non-dilutive royalty financing.Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that on July 22, 2026, the Compensation Committee of Spero’s Board of Directors approved a grant, to be made on August 3rd, of an aggregate of 324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 201
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Spero Therapeutics
Sign Up For FreeTo access detailed company insights
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.... Read More
